The Latest Cardiac and Vascular News
Caesarea, Israel – Oct. 3, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, announces the installation of its SpotLight™ Duo cardiac CT scanner at Lehigh Valley Health Network’s (LVHN) cardiac diagnostic center in Gilbertsville, Pennsylvania. This installation through Lehigh Valley Imaging makes the SpotLight Duo […]
Patients identified with reduced ejection fraction using Eko Health AI were twice as likely to experience heart attacks, heart failure, hospitalization, and all-cause mortality over two years. SAN FRANCISCO, Oct. 2, 2024 /PRNewswire/ — Eko Health, a pioneer in applying artificial…
WASHINGTON, Oct. 1, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) announced today during their Annual Scientific Meeting the launch of a new journal, JCF-Intersections (JCF-I), in partnership with Elsevier. This new journal will join the JCF Family of Journals, led by…
Study will assess the Company’s Next-Generation device under Intracardiac Echocardiography (ICE) imaging for Left Atrial Appendage Occlusion (LAAO) procedures. NASHUA, N.H., Oct. 1, 2024 /PRNewswire/ — Conformal Medical, Inc. today announced the initiation of the GLACE Study. This…
REHOVOT, Israel–(BUSINESS WIRE)–Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market clearance for ShortCut™ – the world’s first dedicated leaflet modification device, enabling valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures […]
– Results from the placebo-controlled study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) were presented in a Late Breaking Clinical Trial Plenary Session at the HFSA Annual Scientific Meeting 2024 – – Data showed patients treated with HU6…
BENTONVILLE, Ark., Sept. 30, 2024 /PRNewswire/ — HeartX, powered by HealthTech Arkansas and MedAxiom — along with numerous leading cardiology practices in Arkansas and around the country — has selected four startup healthcare companies to participate in its 2024 accelerator program….
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions by Anjali T. Owens, M.D., Medical Director of the Center for Inherited Cardiac Disease and Assistant Professor of Medicine at the University of Pennsylvania.
